Ignite Creation Date:
2024-05-05 @ 5:16 PM
Last Modification Date:
2024-10-26 @ 9:30 AM
Study NCT ID:
NCT00422903
Status:
COMPLETED
Last Update Posted:
2016-05-12
First Post:
2007-01-16
Brief Title:
Letrozole In Combination With Lapatinib In Neoadjuvant Treatment Of Early Breast Cancer
Sponsor:
GlaxoSmithKline
Organization:
GlaxoSmithKline
Study Overview
Official Title:
Letrozole Versus Letrozole Plus Lapatinib GW572016 in Hormone-sensitive HER-2 Negative Operable Breast Cancer A Double Blind Randomized Phase II Study With Biomarker Evaluation
Status:
COMPLETED
Status Verified Date:
2016-03
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
Evaluate the percentage of clinical objective responses cOR in patients with HER2 negative early breast cancer treated with pre operative neoadjuvantlapatinib and letrozole
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None